Key Highlights
- $15 million raised in Series E investment to fuel Truveris’ growth and technology enhancement.
- Investment led by Canaan Partners and New Leaf Venture Partners, reaffirming their commitment.
- Truveris’ technology aims to transform pharmacy benefit management by increasing transparency and reducing costs.
Source: Business Wire
Notable Quotes
- “This financing round represents a further validation of our industry-leading solutions and ongoing growth potential,” – Nanette Oddo, CEO at Truveris
- “What made Truveris unique since its inception has been its singular focus on using technology to address one of the biggest benefit challenges facing employers – escalating pharmacy spend,” – Stephen Bloch, General Partner at Canaan Partners
- “We are pleased to increase our investment in Truveris and extend our partnership to support the next chapter in the Company’s evolution,” – Vijay Lathi, Managing Director at New Leaf Venture Partners
SoHC's Take
Truveris’ recent funding is a significant testament to its impactful approach in the healthcare technology sector, specifically in pharmacy cost containment. The company’s focus on replacing outdated PBM models with a technology-driven, transparent system not only demonstrates innovative leadership but also addresses crucial cost issues faced by employers today. This strategic infusion of capital indicates robust confidence from seasoned investors and underscores the essential role of advanced technology in reshaping healthcare expenditure.
